9 Neuren is undervalued given the potential. We value Neuren on a probabilityweighted DCF valuation at 17 cents base case and 21 cents optimistic case.
Our target
price is 17 cents which sits at the low point of this range. We see the market marking up Neuren as Motiva and NNZ-2566 IV near the end of their Phase II trials and oral
NNZ-2566’s opportunity across Autism Spectrum Disorders becomes substantial. Neuren’s Phase II trial of Motiva is going to be the big one lads.......I think.
nine key reasons to buy neuren, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
-0.130(0.85%) |
Mkt cap ! $1.944B | |||
| Open | High | Low | Value | Volume |
| $15.19 | $15.47 | $15.07 | $6.450M | 422.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1938 | $15.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.29 | 54 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |